23.05 0.00 (0.00%)
After hours: 4:59PM EDT
|Bid||23.03 x 800|
|Ask||23.05 x 2900|
|Day's Range||22.79 - 23.59|
|52 Week Range||12.81 - 25.40|
|Beta (3Y Monthly)||0.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2019 - Aug 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.29|
Radius Health (RDUS) delivered earnings and revenue surprises of 9.41% and 0.64%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Abaloparatide-Patch SPA agreement with FDA includes a non-inferiority margin of 2% for the difference in percentage change in lumbar spine BMD at 12 months (i.e. WALTHAM, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (RDUS) today announced the randomization of the first patient in the Phase 3 wearABLe clinical trial studying the safety and efficacy of abaloparatide-transdermal patch (abaloparatide-patch) in the treatment of postmenopausal patients with osteoporosis at high risk for fracture.
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WALTHAM, Mass., July 23, 2019 -- Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter 2019 financial results on Wednesday, August 7th, 2019. The.
WALTHAM, Mass., July 17, 2019 -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Compensation Committee of the Company’s Board of.
If you're interested in Radius Health, Inc. (NASDAQ:RDUS), then you might want to consider its beta (a measure of...
The CHMP provides an unfavorable feedback to Amgen's (AMGN) marketing application for Evenity to treat severe osteoporosis in postmenopausal women with risk of fracture.
Is Radius Health Inc (NASDAQ:RDUS) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
Radius Health Inc NASDAQ NMS:RDUSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for RDUS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding RDUS are favorable, with net inflows of $2.53 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
WALTHAM, Mass., June 04, 2019 -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona, Chief Financial Officer and Joe Kelly, Senior Vice President of Sales.
WALTHAM, Mass., May 10, 2019 -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona, Chief Financial Officer and Joe Kelly, Senior Vice President of Sales and.
Radius Health (RDUS) delivered earnings and revenue surprises of 1.05% and -14.22%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
TYMLOS® U.S. net sales were $29.8 million in the first quarter of 2019 doubling over the first quarter of 2018. TYMLOS continued increasing its share in the U.S. anabolic.
The Waltham, Massachusetts-based company said it had a loss of 94 cents per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...